黄体生成素释放激素-A治疗前列腺癌去势后复发转移九例报告

目的　评估黄体生成素释放激素 A(LHRH A)对前列腺癌去势术后复发或转移患者的治疗效果。　方法　对 9例经活检病理确诊的前列腺癌去势术后复发转移患者应用LHRH A治疗 ,观察分析疗效。　结果　 9例中完全好转 (各项检查正常 ) 4例 ,其中维持 7年、3年、2年、1年各 1例 ;显著好转 (各项检查迅速明显好转或部分正常 ) 2例 ,稳定 (治疗 1个月PSA下降、前列腺硬结缩小 ,转移灶稳定 ) 3例。应用LHRH A者阴茎明显萎缩。　结论　LHRH A治疗对前列腺癌去势后复发或转移患者 ,大部分可获得明显效果 ,但随时间推移也可能产生耐药 ,疗效取决于前列腺癌细胞对药物的敏感性。

LHRH-A for treating prostatic cancer with the occurrence of metastasis after castration (report of 9 cases)

Objective To evaluate the use of LHRH A for treating prostatic cancer with the occurrence of metastasis or recurrence after castration. Methods LHRH A has been instituted to 9 cases of pathologically verified prostatic cancer with the occurrence of metastasis or recurrence after castration.The therapeutic results were studied. Results Ideal improvement was noted in 4 with all the parameters turned normal.These 4 patients have survived well for 7,3,2 and 1 year respectively.Marked improvement occurred in 2 with part of the parameters turned normal or markedly improved shortly after the treatment.The condition of 1 patient became stable with drop of blood PSA and shrinkage of the prostatic mass.In 3 patients,the metastatic lesion became stable.with the use of LHRH A,the penis became markedly atrophic. Conclusions LHRH A is markedly effective in most cases of prostatic cancer with the occurrence of metastasis or recurrence after castration.The therapeutic efficacy depends on the sensitivity of the prostate cancer cells to the drug.Drug resistance may issue as time goes by.